A study to evaluate AZD2693 in participants who are carriers of the PNPLA3 148M Risk Allele with non-cirrhotic non-alcoholic steatohepatitis with fibrosis - FORTUNA

Exclusion Criteria

• :
• Participants are excluded from the study if any of the following criteria apply:
• Medical Conditions
• 1.Liver disease of other aetiologies (eg, alcoholic steatohepatitis; drug-induced, viral or autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; hemochromatosis; alpha-1 antitrypsin deficiency; Wilson’s disease)
• 2.History of cirrhosis and/or hepatic decompensation, including ascites, hepatic encephalopathy, or variceal bleeding.
• 3.Historical persistent or pre-existing renal disease marked by eGFR < 40 mL/min/1.73 m2 (as defined by Kidney Disease Improving Global Outcomes guidelines).
• 4.Confirmed platelet count outside the normal range at the screening visit.
• 5.Any of the following confirmed at the screening visit:
• (a) ALT > 5.0 × ULN
• (b) TBL > 1.5 mg/dL (TBL > 1.5 mg/dL is allowed if conjugated bilirubin is < 1.5 × ULN)
• (c) INR > 1.3
• (d) ALP > 1.5 × ULN (unless the ALP elevation is not from hepatic origin as determined by a bone-specific ALP)